Recently, Tanaka et al. described acquired resistance to adagrasib in an NSCLC patient with 10 secondary genetic mutations on the RAS–RAF–MEK–ERK pathway [85]. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.